Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00856414
Other study ID # MA-BTX-0806
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 2009
Est. completion date April 2009

Study information

Verified date January 2019
Source Allergan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the patient satisfaction and onset of effect following treatment with botulinum toxin Type A in the treatment of glabellar rhytids (frown lines)


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date April 2009
Est. primary completion date April 2009
Accepts healthy volunteers No
Gender Female
Age group 35 Years to 55 Years
Eligibility Inclusion Criteria:

- Female subjects of any race, 35-55 years of age

- Moderate to severe glabellar wrinkles (lines between the eyebrows)

Exclusion Criteria:

- Previous botulinum toxin therapy

- Subjects who are pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control

- Subjects planning a facial cosmetic procedure or visible scars

- Previous cosmetic surgery to the upper face

- Medical condition that may increase their risk of exposure to botulinum toxin including diagnosed Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis, or any other disease that might interfere with neuromuscular function

- History of facial nerve palsy

- Allergy or sensitivity to any component of the study medication

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
botulinum toxin Type A
20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Allergan

Country where clinical trial is conducted

United States, 

References & Publications (1)

Beer KR, Boyd C, Patel RK, Bowen B, James SP, Brin MF. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. J Drugs Dermatol. 2011 Jan;10(1):39-44. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The First Visit Onset of Efficacy as Measured by Physician Assessment The first visit onset of efficacy as measured by physician assessment. Onset is determined by a yes/no answer to the question "Since injecting the patient, have you noticed any effect on the appearance of the patient's frown lines (lines between the eyebrows)?" at days 2, 3, 4, 7, and 14. 14 Days
Primary The First Visit Onset of Efficacy as Measured by Subject Assessment The first visit onset of efficacy as measured by subject assessment. Onset is determined by a yes/no answer to the question "Since being injected, have you noticed any effect on the appearance of your frown lines (lines between the eyebrows)?" at days 2, 3, 4, 7, and 14. 14 Days
Secondary Average Subject Assessment Score in Improvement of Appearance of Frown Lines Average subject assessment score in improvement of appearance of frown lines (lines between the eyebrows) as measured by a 7-point scale (1=very much improved and 7=very much worse)on a daily basis. The average scores over the 1st diary week (1-7 days) and the 2nd diary week (8-14 days) are presented. 14 Days
Secondary Change From Baseline in Patient Satisfaction as Measured by Facial Line Outcome (FLO) Questionnaire Score Change from baseline in patient satisfaction as measured by FLO questionnaire comprised of 11 items that assess subject's perceptions about specific aspects of their facial lines for the previous 7 days. Each question is scored on a 11-point scale (0=not at all, 5=somewhat, 10=very much) and the sums are converted to the total FLO score. The minimum total FLO score is 0 (worst) and the maximum total FLO score is 100 (best). The total FLO score was calculated at baseline and Day 14. A positive number change from baseline indicates an improvement. Baseline, Day 14
Secondary Percentage of Patients Reporting Self-Perception of Age (SPA) Percentage of patients reporting their SPA. SPA is measured by a questionnaire. Patients were asked to compare their facial appearance to their current age. Response options were "Looking younger", "Looking current age", and "Looking older". Results for each response are presented for Baseline and Day 14. Baseline, Day 14
See also
  Status Clinical Trial Phase
Completed NCT04276753 - A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects N/A
Completed NCT06125912 - A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging N/A
Completed NCT02580370 - Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines Phase 3
Recruiting NCT01583478 - Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Phase 4
Completed NCT02003833 - Poly-L-lactic Acid for Skin Quality Phase 4
Completed NCT01447342 - A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines Phase 2/Phase 3
Completed NCT00974480 - Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging N/A
Completed NCT00986570 - Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face Phase 3
Completed NCT00272610 - Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin Phase 2
Recruiting NCT03730649 - Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure Early Phase 1
Completed NCT03312543 - Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles N/A
Active, not recruiting NCT05349799 - TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines N/A
Completed NCT03677258 - Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy N/A
Withdrawn NCT05854628 - The Role of Red Flavonoid in Photoaging N/A
Completed NCT01981980 - Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation N/A
Not yet recruiting NCT00767156 - Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging N/A
Recruiting NCT05813054 - Clinical Study to Evaluate the Anti-aging Efficacy of Dermial® N/A
Not yet recruiting NCT04485091 - TCA Peel and Photobiomodulation for Hand Rejuvenation Phase 2
Completed NCT05457491 - Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE) Phase 1
Completed NCT01237977 - Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines Phase 3